Paciente con síndrome de intestino corto y progresión atípica de adenocarcinoma de endometrio

  1. Novo-Veleiro, I 1
  2. Macía-Rodríguez, C 1
  3. Alende-Castro, V 1
  4. Páez-Guillán, E 1
  5. García-Villafranca, A 1
  1. 1 Servicio de Medicina Interna. Complejo Hospitalario Universitario de Santiago de Compostela (A Coruña). España
Revista:
Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

ISSN: 2530-0792

Ano de publicación: 2016

Volume: 0

Número: 1

Páxinas: 32-34

Tipo: Artigo

DIALNET GOOGLE SCHOLAR lock_openAcceso aberto editor

Outras publicacións en: Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

Resumo

The most common location of distant metastasis of endometrial adenocarcinoma is the lung, although sometimes it could appear soft tissue involvement. Short bowel syndrome can potentially cause serious electrolite changes that require a global management. Patient admitted for severe electrolyte changes secondary to a short bowel syndrome after an intestinal resection. Octreotide LAR was successfully used to control intestinal losses. During the outpatient follow up was detected two soft tissue masses in gluteal region compatible with tumour progression of an endometrial adenocarcinoma diagnosed 10 years before. The usefulness of octreotide to control chronic diarrhoea in short bowel syndrome and other diseases should be taken into account as an option for the management of these diseases. The presence of soft tissue masses in a patient with a history of endometrial adenocarcinoma should alert on the possibility of tumour progression at that level.

Referencias bibliográficas

  • Kurra V, Krajewski KM, Jagannathan J, Giardino A, Berlin S, Ramaiya N. Typical and atypical metastatic sites of recurrent endometrial carcinoma. Cancer Imaging. 2013 Mar 26; 13: 113-22.
  • Kumpf VJ. Pharmacologic management of diarrhea in patients with short bowel syndrome. J Parenter Enteral Nutr. 2014 May; 38(1 Suppl): 38S-44S.
  • Nehra V, Camilleri M, Burton D, Oenning L, Kelly DG. An open trial of octreotide long-acting release in the management of short bowel syndrome. Am J Gastroenterol. 2001 May; 96(5): 1494-8.
  • Gómez-Herrera E, Farías-Llamas OA, Gutiérrez-de la Rosa JL, Hermosillo-Sandoval JM. The role of long-acting release (LAR) depot octreotide as adjuvant management of short bowel disease. Cir Cir. 2004 Sep-Oct; 72(5): 379-86.
  • Gregersen T, Grønbæk H, Worsøe J, Schlageter V, Laurberg S, Krogh K. Effects of Sandostatin LAR on gastrointestinal motility in patients with neuroendocrine tumors. Scand J Gastroenterol. 2011 Jul; 46(7-8): 895-902.
  • Van den Heuvel B, Peeters M, Hendlisz A, Van den Eynde M, Machiels G, Dero I, et al. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept. Minerva Chir. 2016 Jan 15. [Epub ahead of print].
  • Sohaib SA, Houghton SL, Meroni R, Rockall AG, Blake P, Reznek RH. Recurrent endometrial cancer: patterns of recurrent disease and assessment of prognosis. Clin Radiol. 2007 Jan; 62(1): 28-34; discussion 35-6.
  • Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol. 1984 Jan; 17(1): 85-103.
Fonte de datos: Dialnet